Chinese Biotech Firm Magpie Pharmaceuticals Raises Nearly $15M In Series B Round

Login to View

Guangzhou-based biotechnology company Magpie Pharmaceuticals announced on Monday that it has raised a nearly RMB100 million (US$14.8 million) series B financing round from Chinese venture capital firm Sangel Capital.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Read 3 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription for $359

Enjoy comprehensive and exclusive data you can't find elsewhere!

Subscribe for $359


Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in

China Money Network Subscription

RELATED NEWS